AdjuderaGet started

Supplier

Samsung Bioepis NL B.V.

Delft · NLD

Track this recordWith Adjudera Pro, get alerted before a contract here runs out.

Awards

6

Total awarded

€3.4m

5 joint award(s) counted pro rata

Buyers

4

Sectors

1

Group: SAMSUNG BIOEPIS NL BV(inferred)

Reg. 71719652

Contracts this supplier holds that are running out

16 Sept 2027
estimated
AFLIBERCEPT [40 MG/ ML; SOL INJ; FRS/ SERINGA]- FRASCO
OUTRAS INSTITUIÇÕES DE SAÚDESamsung Bioepis NL B.V.
€344,861
31 Mar 2029
stated
Udbudsnummer 1
Amgros I/SAccord Healthcare AB, Biocon Biologics Ireland Limited, Orion Pharma A/S +2 more
DKK 343,498,469
30 Apr 2030
stated
Udbudsnummer 1
Amgros I/SAmgen Filial Af Amgen Ab Sverige, Orifarm A/S, Samsung Bioepis NL B.V.
DKK 124,000,000

All expiring contracts →

Awards

Awarded	Buyer	Winner	Contract value	Published
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Ranibizumab, ATC S01LA04 für die Zeit 01.09.2024 - 31.08.2026	DAK-Gesundheit	1 0 1 Carefarm GmbH, 2care4 ApS, Aaragon Pharma s.r.o +15 more	—	23 Sept 2026
Udbudsnummer 1	Amgros I/S	Amgen Filial Af Amgen Ab Sverige, Orifarm A/S, Samsung Bioepis NL B.V.	DKK 124,000,000	22 Sept 2026
Udbudsnummer 1	Amgros I/S	Accord Healthcare AB, Biocon Biologics Ireland Limited, Orion Pharma A/S +2 more	DKK 343,498,469	22 Sept 2026
AFLIBERCEPT [40 MG/ ML; SOL INJ; FRS/ SERINGA]- FRASCO	OUTRAS INSTITUIÇÕES DE SAÚDE	Samsung Bioepis NL B.V.	€344,861	21 Sept 2026
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Denosumab, ATC M05BX04 für die Zeit 01.07.2025 - 30.06.2026 (zzgl. Verlängerungsoption 1x 12 Monate)	DAK-Gesundheit	1 4 U Pharma GmbH, Abacus Medicine A/S, Accord Healthcare S.L.U. +20 more	—	31 Aug 2026
Eculizumab	Servicio de Salud - Servicios Centrales	Amgen SA, Samsung Bioepis NL B.V.	€6,093,984	25 Mar 2025